Early Access Program for Nusinersen There has been a lot of activity in the clinical trial space for the treatment of Spinal Muscular Atrophy (SMA) over the last two years, and Nusinersen, has been identified as the first effective drug to treat SMA Type 1. Developed in California, Nusinersen (know in the USA […]
INMR diagnostic meetings schedule
Please see below for dates of The Institute for Neuroscience and Muscle Research (INMR) at The Children’s Hospital at Westmead diagnostic meetings schedule. Genetic Muscle Disease Diagnostic Meeting: As we move away from tissue diagnosis towards genetic diagnosis, this forum is to discuss difficult cases and to pool thoughts on the interpretation of results (incorporating […]
Read full story • Comments are closed
Lifeline for Pompe disease patients
RCH clinicians have worked with the Australian Pompe Association, drug company Genzyme and the Federal government to achieve government-subsidised treatment for late-onset Pompe disease. 12-year-old patient Christian Rivera received his first infusion at the RCH last week. The federal government has listed the only registered treatment for Pompe disease, Myozyme (alglucosidase alfa), on the Life […]
Read full story • Comments are closed
ANN and CRE-NMD Annual Scientific Meeting 2014
Our 2014 Annual Scientific Meeting was a huge success with close to 100 delegates attending, making this our biggest meeting yet! The meeting was held on the 27th and 28th March across The Royal Children’s Hospital and Murdoch Childrens Research Institute in Parkville, Melbourne. Thank you to all those who attended and presented. You all […]
Read full story • Comments are closed